For the Inventor, By the Inventor

Enter assignee name

Rahway, NJ, United States of America

Merck Sharp + Dohme Corp.

USPTO Granted Patents = 2,405

% Expired Patents = 15.9

CIPO Patents = 74

EPO Patents = 1,348

Trademarks = 158

Forward Citations = 11,974

Loading Chart...

Loading Chart...

3,387 inventors (with patents filed for the assignee):

Scott D Kuduk (80 out of 118 patents)

Andrew William Stamford (74 out of 125 patents)

Jared N Cumming (69 out of 79 patents)

4. Leslie Joseph Street (68 out of 70 patents)

5. Amjad Ali (61 out of 67 patents)

6. Michael D Altman (56 out of 59 patents)

7. Raymond Baker (56 out of 63 patents)

8. Angus Murray MacLeod (53 out of 58 patents)

9. Christopher John Swain (53 out of 54 patents)

10. Joseph A Kozlowski (52 out of 104 patents)

11. Timothy Harrison (51 out of 73 patents)

12. Ian M Bell (49 out of 73 patents)

13. Jose Luis Castro Pineiro (48 out of 56 patents)

14. Janusz Jozef Kulagowski (47 out of 73 patents)

15. Tesfaye Biftu (45 out of 84 patents)

Core Competencies:

Adenosine Receptor Antagonists

Migraine Treatments

Plasma Kallikrein Inhibitors

Antibacterial Agents

Cancer Therapies

PD-1 Antibodies

Histone Deacetylase Inhibitors

Orexin Receptor Agonists

KRAS Inhibitors

PCSK9 Antagonists

Vaccines

Immunogenicity Enhancements

2,405 patents: Sort by Forward Citations

1. 12466831 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-11-11),

2. 12459933 - Compounds and methods of use thereof as antibacterial agents (2025-11-04),

3. 12459927 - Plasma kallikrein inhibitors (2025-11-04),

4. 12458633 - Treatment of migraine (2025-11-04),

5. 12458632 - Treatment of migraine (2025-11-04),

6. 12454525 - IL4I1 inhibitors and methods of use (2025-10-28),

7. 12448384 - Diacylglyceride O-acyltransferase 2 inhibitors (2025-10-21),

8. 12441792 - Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof (2025-10-14),

9. 12441730 - PRMT5 inhibitors (2025-10-14),

10. 12440496 - Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes (2025-10-14),

11. 12435133 - Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof (2025-10-07),

12. 12435077 - Oxazolidinone compound and methods of use thereof as an antibacterial agent (2025-10-07),

13. 12428411 - Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors (2025-09-30),

14. 12428397 - Factor XI activation inhibitors (2025-09-30),

15. 12427187 - Glucose-responsive insulin conjugates (2025-09-30),

Company Overview

Merck Sharp & Dohme Corp., headquartered in Rahway, NJ, is a leading global healthcare company specializing in pharmaceutical research and development. The organization focuses on innovative therapies across various domains, including adenosine receptor antagonists, migraine treatments, and plasma kallikrein inhibitors. Additionally, it is engaged in the development of antibacterial agents, cancer therapies, PD-1 antibodies, histone deacetylase inhibitors, and orexin receptor agonists, contributing significantly to advancements in medical science.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

2,405 Patents

#2 in Rahway, NJ

#16 in New Jersey

#205 in US

#413 in the World

Rahway, NJ, United States of America

Merck Sharp + Dohme Corp.

Forward Citations = 11,974

3,387 inventors:

Scott D Kuduk (80 out of 118 patents)

Andrew William Stamford (74 out of 125 patents)

Jared N Cumming (69 out of 79 patents)

4. Leslie Joseph Street (68 out of 70 patents)

5. Amjad Ali (61 out of 67 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Merck Sharp + Dohme Corp.. Retrieved from https://idiyas.com/company/merck-sharp-plus-dohme

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…